Shares of Danaher DHR fell 0.4% in pre-market trading after the company reported Q2 results.
Quarterly Results
Earnings per share rose 70.83% year over year to $2.46, which beat the estimate of $2.05.
Revenue of $7,218,000,000 up by 36.27% from the same period last year, which beat the estimate of $6,720,000,000.
Looking Ahead
Danaher said it expects Q3 sales growth will be in mid-to high teens percentage.
Details Of The Call
Date: Jul 22, 2021
Time: 08:00 AM
ET Webcast URL: http://investors.danaher.com/events-presentations
Recent Stock Performance
Company's 52-week high was at $287.00
52-week low: $190.34
Price action over last quarter: Up 7.32%
Company Overview
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, including the Fortive separation in 2016, Danaher now focuses primarily on manufacturing scientific instruments and consumables in three segments: life sciences, diagnostics, and environmental and applied solutions. In late 2019, Danaher separated from its dental business through an initial public offering process, and in early 2020, it acquired GE's Biopharma business, now called Cytiva, which added to its life sciences segment.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
